Discover how ADCs are advancing oncology, the regulatory challenges they face, and the promise they hold for the future of ...

Scientists have created a novel technology for developing antibody (M6P) conjugates without enzyme modification in vitro, ...

Allink Biotherapeutics, a Chinese startup specializing in bispecific antibodies and antibody-drug conjugates, raises $42 ...

Cancer treatment has entered a revolutionary phase with advancements in immunotherapy, a field that employs the immune system ...

Sac-TMT, also known as SKB264 or MK-2870, represents the first asset in Kelun’s multitarget, multibillion-dollar ADC ...

The funds will be utilised to progress the global clinical development of Allink's lead candidates, ALK201 and ALK202.

Erika P. Hamilton, MD, discusses antibody-drug conjugates in multiple types of breast cancer, and when to use these drugs in ...

Adcendo joins a growing group of biotechs working to usher the next generation of antibody-drug conjugates to the market.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today highlighted ...

With Amgen’s MariTide results at the lower end of investors’ expectation of 20% to 25% weight loss, the much-anticipated ...